Zhejiang Jolly Pharmaceutical Co.,LTD (SHE:300181)

SHE:300181 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,741	2,569	1,937	1,787	1,450	1,086
Other Revenue	7.98	8.95	5.2	18.23	7.26	5.32
Revenue	2,749	2,578	1,942	1,805	1,457	1,091
Revenue Growth (YoY)	16.52%	32.71%	7.61%	23.86%	33.60%	19.72%
Cost of Revenue	1,080	1,019	616.36	534.65	420.35	362.9
Gross Profit	1,669	1,559	1,326	1,271	1,037	727.98
Selling, General & Admin	955.49	949.08	874.18	921.45	794.25	601.17
Research & Development	58.01	71.94	79.38	64.43	45.63	30.39
Other Operating Expenses	-58.97	-58.7	-49.99	-42.32	-28.31	-21.62
Operating Expenses	961.92	968.57	904.42	948.8	812.78	610.52
Operating Income	707.32	590.51	421.66	321.71	224.26	117.46
Interest Expense	-11.85	-9.29	-7.62	-8.32	-12.07	-17.44
Interest & Investment Income	9.35	15.95	22	4.64	4.41	2.05
Currency Exchange Gain (Loss)	0	0	0	-0	-	-
Other Non Operating Income (Expenses)	9.71	-0.47	0.18	-0.01	-1.13	1.65
EBT Excluding Unusual Items	714.52	596.7	436.21	318.02	215.47	103.71
Gain (Loss) on Sale of Investments	-1.99	-0.66	-0.1	0.08	0.52	0.39
Gain (Loss) on Sale of Assets	0.1	0.35	0.28	-9.71	-1.92	-0.08
Asset Writedown	-8.06	-8.06	-0.53	-	-	-
Other Unusual Items	-4.25	8.36	10.78	15.74	8.24	5.17
Pretax Income	700.32	596.69	446.64	324.12	222.31	109.18
Income Tax Expense	105.02	80.73	55.88	38.6	30.33	13.87
Earnings From Continuing Operations	595.3	515.96	390.76	285.52	191.98	95.31
Net Income to Company	595.3	515.96	390.76	285.52	191.98	95.31
Minority Interest in Earnings	-10.08	-8.19	-7.83	-12.51	-12.58	-6.51
Net Income	585.22	507.77	382.94	273.01	179.41	88.8
Net Income to Common	585.22	507.77	382.94	273.01	179.41	88.8
Net Income Growth	21.58%	32.60%	40.27%	52.17%	102.03%	246.98%
Shares Outstanding (Basic)	696	696	696	607	619	609
Shares Outstanding (Diluted)	696	696	696	607	619	609
Shares Change (YoY)	-0.09%	-0.10%	14.76%	-1.93%	1.64%	0.12%
EPS (Basic)	0.84	0.73	0.55	0.45	0.29	0.15
EPS (Diluted)	0.84	0.73	0.55	0.45	0.29	0.15
EPS Growth	21.70%	32.73%	22.22%	55.17%	98.77%	246.56%
Free Cash Flow	56.21	34.16	156.75	140.56	103.84	221.34
Free Cash Flow Per Share	0.08	0.05	0.23	0.23	0.17	0.36
Dividend Per Share	0.600	0.600	0.450	0.300	0.200	0.100
Dividend Growth	33.33%	33.33%	50.00%	50.00%	100.00%	400.00%
Gross Margin	60.72%	60.48%	68.27%	70.38%	71.16%	66.73%
Operating Margin	25.73%	22.91%	21.71%	17.82%	15.39%	10.77%
Profit Margin	21.29%	19.70%	19.71%	15.12%	12.31%	8.14%
Free Cash Flow Margin	2.04%	1.32%	8.07%	7.79%	7.12%	20.29%
EBITDA	777.35	657.69	483.23	378.43	277.87	171.31
EBITDA Margin	28.28%	25.51%	24.88%	20.96%	19.07%	15.70%
D&A For EBITDA	70.03	67.18	61.58	56.72	53.61	53.85
EBIT	707.32	590.51	421.66	321.71	224.26	117.46
EBIT Margin	25.73%	22.91%	21.71%	17.82%	15.39%	10.77%
Effective Tax Rate	14.99%	13.53%	12.51%	11.91%	13.64%	12.71%
Revenue as Reported	2,749	2,578	1,942	1,805	1,457	1,091
Advertising Expenses	-	28	15.71	675.37	528.45	377.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.